Advertisement

Structure-Onset Relationship of Steroidal Neuromuscular Blocking Agents

  • J. Mark
  • K. H. Wierda
  • Johannes H. Proost
Conference paper

Abstract

Since the introduction of the long-acting agent pancuronium in clinical practice several other related steroidal non-depolarizing neuromuscular blocking agents have been synthetized, developed and finally tested in clinical practice to investigate their safety and efficacy. Vecuronium, the monoquaternary analogue of pancuronium, was introduced in clinical practice as it showed two major improvements over pancuronium: a better time course of action, i.e., a shorter duration and a faster recovery, and an higher selectivity for the nicotinic cholinoceptor. This increased selectivity resulted in a remarkable, cardiovascularly clean profile comparable to that of the long-acting compound pipecuronium, the 2,16 piperazino analogue of pancuronium, which was developed at almost the same time. All mentioned compounds so far showed a significantly longer duration of action than the depolarizing agent succinylcholine. The main reason, however, to use this relatively “dirty” depolarizing agent in large numbers of patients, was its rapid onset of action, promoting safety by allowance of early intubation.

Keywords

Onset Time Early Intubation Receptor Affinity Neuromuscular Blocking Agent Effect Compartment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bowman WC, Rodger IW, Houston J, Marshall RJ, Mclndewar I. Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988,69:57–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981,6:429–453.PubMedCrossRefGoogle Scholar
  3. 3.
    Donati F, Meistelman C. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J Pharmacokinet Biopharm 1991,19:537–552.PubMedCrossRefGoogle Scholar
  4. 4.
    Hull CJ. Pharmacokinetics for Anaesthesia. Butterworth-Heinemann Ltd 1991, ISBN 075061420X, pages 333–336.Google Scholar
  5. 5.
    Wierda JMKH, Proost JH, Muir AW, Marshall RJ. Design of drugs for rapid onset. Anaesth Pharmacol Rev 1993,1:57–68.Google Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • J. Mark
    • 1
    • 2
  • K. H. Wierda
    • 1
    • 2
  • Johannes H. Proost
    • 1
    • 2
  1. 1.Research Group for Experimental Anesthesiology and Clinical PharmacologyUniversity HospitalGroningenThe Netherlands
  2. 2.Department of Pharmacology and TherapeuticsUniversity Centre for PharmacyGroningenThe Netherlands

Personalised recommendations